Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

CIBA-GEIGY VOLTAREN NEW Rxs ACHIEVE 9.4% SHARE of the U.S. retail non-steroidal anti-inflammatory drug market for the week ended Oct. 18, up from 4.1% during the month of September, prescription audit firm Pharmaceutical Data Services reports in its most recent Alpha-Gram. "Voltaren (diclofenac) does not appear to be expanding the market, but is gaining share from competition," the Alpha-Gram states. "About 40% of Voltaren new patients have been on some other NSAID therapy within the past six months. This figure is significantly higher than the NSAID class average of 15%, and is to be expected for a new market entrant." Approved by FDA on July 28, Voltaren was launched at the beginning of September. However, the drug has been marketed outside the U.S. for almost 15 years. Sales volume was about $500 mil. in 1987, according to Ciba-Geigy, with total prescriptions in excess of 60 mil. Voltaren's market share increase in October came at the expense of generic ibuprofen, Merck's Clinoril, Pfizer's Feldene and Syntex' Naprosyn. According to PDS data, generic ibuprofen declined from 24.2% to 22.8%, Clinoril slid to 5.7%, from 6%, Feldene dropped from 9.8% to 8.8% and Naprosyn edged down to 18.4%, from 19%. Motrin, Upjohn's branded ibuprofen product, showed a fractional market share increase between the month of September and the seven days ended Oct. 18, climbing from 12% to 12.1%. In addition to the 40% switched patient figure reported for Voltaren, PDS data for September show 24% of new Feldene prescriptions written for patients switching from another NSAID product. Clinoril and Naprosyn are next, at 20% and 13%, respectively, followed by generic ibuprofen at 6%.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts